Elpis Biopharmaceuticals and Singapore General Hospital are joining forces to develop effective and accessible next generation cancer therapies.
Sanofi is advancing a microbiome-based acne vaccine in partnership with A*STAR and the National Healthcare Group to flip how acne is treated on its head.
Supported by Singapore’s research ecosystem, Eli Lilly expands its R&D efforts in the region to drive next-generation AI-powered digital health technology research.
By harnessing Singapore’s ecosystem of partners and support, RNA technology company Mirxes has established a global presence and works toward making early disease detection accessible worldwide.
Beyond coping with the disease through exercise and healthy eating, patients may soon see novel therapeutics that prevent further damage to the liver.
A win-win public-private research partnership for better eye health.